Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SUN-0864
- Development stage
- Phase 1
- Lead developer
- Superluminal Medicines
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SUN-0864 is an orally administered, selective, biased small-molecule agonist of the melanocortin-4 receptor (MC4R) developed by Superluminal Medicines. Engineered using generative biology and chemistry, the compound is designed to selectively activate specific signaling pathways within the MC4R system to regulate energy homeostasis and appetite while avoiding common class-associated side effects such as skin darkening and cardiovascular issues. SUN-0864 is being evaluated in Phase 1 clinical trials for the treatment of obesity, overweight, and rare genetic forms of obesity, including Bardet-Biedl syndrome (BBS) and hypothalamic obesity.
02
Targets
MC4R (Melanocortin 4 receptor)
Beyond the preview
Go deeper on SUN-0864.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SUN-0864.